Screening for Gene-Editing Eligibility in Inherited Disorders

Abstract

Gene-editing technologies, particularly CRISPR-Cas9 and related systems, have fundamentally transformed the therapeutic landscape for inherited disorders. This review examines the critical process of screening for gene-editing eligibility, integrating current evidence, clinical guidelines, and practical implications for healthcare professionals. By elucidating the epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, management, and emerging therapies, this article provides a comprehensive resource for clinicians considering gene-editing options in patients with inherited diseases.

Introduction

Inherited disorders, encompassing a wide spectrum of single-gene and polygenic conditions, represent a significant global health burden. With the advent of gene-editing technologies, particularly CRISPR-Cas9, there is renewed optimism for curative interventions. However, the success of gene-editing therapies hinges on meticulous patient selection through evidence-based screening. This process requires consideration of genetic, phenotypic, and ethical factors to ensure safety and efficacy. This review synthesizes current literature and clinical guidelines to delineate optimal screening practices for gene-editing eligibility in inherited disorders, targeting clinicians and healthcare professionals involved in multidisciplinary care.

Epidemiology / Disease Burden

Inherited disorders affect millions worldwide, with monogenic diseases such as sickle cell anemia, cystic fibrosis, and Duchenne muscular dystrophy constituting significant morbidity and mortality. According to global estimates, approximately 5-7% of the population harbors a rare genetic disorder. The burden is particularly high in regions with higher rates of consanguinity and limited access to genetic counseling. Early identification and intervention are critical, as untreated genetic diseases often result in progressive dysfunction, disability, or early death. Screening for gene-editing eligibility thus holds potential to alleviate disease burden and improve long-term outcomes.

Pathophysiology

Inherited disorders arise from pathogenic variants in DNA, leading to aberrant protein function or regulation. Gene-editing aims to correct these underlying genetic defects at the molecular level, offering the possibility of permanent cure. Mechanistically, CRISPR-Cas9, TALENs, and ZFNs facilitate targeted DNA breaks and subsequent repair, which can disrupt, correct, or replace dysfunctional genes. The suitability for gene-editing depends on factors such as the type of mutation (gain-of-function, loss-of-function), gene size, and the feasibility of efficient delivery and editing in target tissues. Preclinical models have demonstrated variable efficacy and off-target effects, necessitating careful assessment during pre-treatment screening.

Risk Factors

Identifying patients eligible for gene-editing requires comprehensive evaluation of genetic and clinical risk factors. Key considerations include the specific pathogenic variant, zygosity, disease severity, age, comorbidities, and prior response to standard therapies. Certain mutations, such as single-nucleotide changes or small deletions, are more amenable to precise gene-editing, while large deletions or complex rearrangements pose greater challenges. Additionally, immunological factors, including pre-existing immunity to gene-editing vectors (e.g., AAV), may affect eligibility and safety. Family history and inheritance patterns also inform risk stratification and counseling.

Clinical Features

The phenotypic spectrum of inherited disorders is broad, encompassing variable age of onset, organ involvement, and disease progression. Accurate phenotyping is essential for eligibility screening, as it influences the timing and expected benefit of gene-editing intervention. For example, patients with early-onset severe phenotypes may require urgent intervention, while those with milder forms or late-onset manifestations may be better suited for surveillance or conventional therapies. Clinical features must be correlated with genotype to stratify patients and predict therapeutic response.

Diagnosis

Diagnosis of inherited disorders relies on a combination of clinical assessment, family history, biochemical testing, and, crucially, molecular genetic analysis. Next-generation sequencing (NGS), whole-exome sequencing (WES), and targeted gene panels are instrumental in identifying pathogenic variants. For gene-editing eligibility, precise molecular characterization—including variant type, location, and allelic context—is mandatory. Pre-therapeutic assessment should also include evaluation of organ function, disease stage, and potential contraindications. Genetic counseling is integral to the diagnostic process, ensuring informed decision-making and ethical compliance.

Treatment & Management

Current management of inherited disorders typically involves supportive care, pharmacotherapy, enzyme replacement, or hematopoietic stem cell transplantation. Gene-editing offers the potential for disease modification or cure, particularly in disorders with clear monogenic etiology. Patient selection for gene-editing must integrate clinical stability, absence of advanced organ dysfunction, and lack of alternative curative options. Multidisciplinary care teams—including geneticists, specialists, and ethicists—are essential to optimize treatment planning and follow-up. Informed consent and risk-benefit analysis are mandatory components of pre-treatment counseling.

Recent Advances / Emerging Therapies

Recent advances in gene-editing have propelled multiple clinical trials targeting inherited hematologic, neuromuscular, and metabolic disorders. CRISPR-based therapies have demonstrated promising early results in conditions such as sickle cell disease and beta-thalassemia, with reports of transfusion independence and symptomatic improvement. Base editing, prime editing, and epigenetic editing represent next-generation approaches aiming for greater precision and efficiency. Despite these advances, challenges remain, including off-target effects, delivery limitations, immune responses, and long-term safety concerns. Ongoing research is focused on expanding the scope of eligible disorders and refining delivery systems to improve clinical outcomes.

Guideline Recommendations

International guidelines emphasize rigorous eligibility criteria for gene-editing, highlighting the need for confirmed molecular diagnosis, clear genotype-phenotype correlation, and evidence of clinical or biochemical benefit. The American Society of Gene and Cell Therapy (ASGCT) and European Society of Human Genetics (ESHG) recommend multidisciplinary evaluation, comprehensive genetic counseling, and robust informed consent processes. Patients must be screened for contraindications, including underlying malignancy, infections, or significant organ dysfunction. Guidelines also stipulate ongoing post-therapy surveillance to monitor efficacy, durability, and late adverse effects.

Conclusion

Screening for gene-editing eligibility in inherited disorders is a complex, multidimensional process requiring integration of genetic, clinical, and ethical considerations. As gene-editing technologies advance, rigorous screening protocols are essential to maximize benefit, minimize risk, and uphold ethical standards. Clinicians must remain informed about current evidence, emerging therapies, and evolving guidelines to guide optimal patient selection and management. Continued research and multidisciplinary collaboration will be pivotal in expanding access to gene-editing therapies and improving outcomes for individuals with inherited diseases.